Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239620 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CYP1A2HIF1A | |
| SCHEMBL29642341 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CYP1A2HIF1A | |
| SCHEMBL1012317 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CYP1A2HIF1A | |
| SCHEMBL7247150 | 0.86 | CHRM2 (0.48) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1010269 | 0.84 | CYP1A2 (0.54) | CHRM2CHRM1CHRM3CYP1A2HIF1A | |
| SCHEMBL16237251 | 0.83 | CHRM2 (0.37) | CHRM2CHRM1CHRM3CYP1A2HIF1A | |
| SCHEMBL20845556 | 0.83 | CYP1A2 (0.49) | CYP1A2HIF1AALDH1A1 | |
| SCHEMBL24701533 | 0.83 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL31080086 | 0.80 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21124699 | 0.80 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114773318-A | Delta opioid receptor modulating compounds containing six-membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-108025002-B | Delta opioid receptor modulating compounds containing six membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3344248-B1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| EP-2632268-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2615916-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | CHRM2 179/4885CHRM1 146/4885CHRM3 144/4885 |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | CHRM2 4760/4885CHRM1 4753/4885CHRM3 4500/4885 |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | CHRM2 4750/4885CHRM1 4605/4885CHRM3 4690/4885 |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | CHRM2 1007/4885CHRM1 1366/4885CHRM3 1785/4885 |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | CHRM2 179/4885CHRM1 146/4885CHRM3 144/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | CHRM2 1057/4885CHRM1 1271/4885CHRM3 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.